Late Stage Drugs From BioSante and AEterna Zentaris Could Reawaken Interest in Biotech Sector
The Paragon Report Provides Equity Research on BioSante Pharmaceuticals & AEterna Zentaris
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 10/20/11 -- Drug approvals from administrative bodies in both the U.S. and Europe have been pivotal for biotech companies recently. Investors have been particularly sensitive to decisions made on new drugs considering the state of the global economic recovery. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and AEterna Zentaris, Inc. (NASDAQ: AEZS) (TSX: AEZ). Access to the full company reports can be found at:
While there are some success stories in the industry, a number of players are having trouble dealing with the volatile nature of biotechnologies. Research and development costs are extremely high, and the success of a product can sometimes not be measured until late in development. According to Krishan Maggon, a Geneva-based pharmaceuticals consultant, the number of new biotech drugs approved in the U.S. has remained in the 20 to 25 range during the past four years, while in Europe the figure was a record-low 14 last year.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. The company's lead products include LibiGel for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder. Last week the company announced that the independent Data Monitoring Committee (DMC) has completed the seventh unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects.
AEterna Zentaris Inc. is a drug development company specialized in oncology and endocrine therapy. The Company's product pipeline encompasses compounds at all stages of development, from drug discovery through marketed products.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 20.10.2011 - 06:16 Uhr
Sprache: Deutsch
News-ID 1048097
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 140 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Late Stage Drugs From BioSante and AEterna Zentaris Could Reawaken Interest in Biotech Sector
"
steht unter der journalistisch-redaktionellen Verantwortung von
Paragon Financial Limited (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
